Literature DB >> 16492761

An efficient rapid system for profiling the cellular activities of molecular libraries.

Jonathan S Melnick1, Jeff Janes, Sungjoon Kim, Jim Y Chang, Daniel G Sipes, Drew Gunderson, Laura Jarnes, Jason T Matzen, Michael E Garcia, Tami L Hood, Ronak Beigi, Gang Xia, Richard A Harig, Hayk Asatryan, S Frank Yan, Yingyao Zhou, Xiang-Ju Gu, Alham Saadat, Vicki Zhou, Frederick J King, Christopher M Shaw, Andrew I Su, Robert Downs, Nathanael S Gray, Peter G Schultz, Markus Warmuth, Jeremy S Caldwell.   

Abstract

Rapid quantitative methods for characterizing small molecules, peptides, proteins, or RNAs in a broad array of cellular assays would allow one to discover new biological activities associated with these molecules and also provide a more comprehensive profile of drug candidates early in the drug development process. Here we describe a robotic system, termed the automated compound profiler, capable of both propagating a large number of cell lines in parallel and assaying large collections of molecules simultaneously against a matrix of cellular assays in a highly reproducible manner. To illustrate its utility, we have characterized a set of 1,400 kinase inhibitors in a panel of 35 activated tyrosine-kinase-dependent cellular assays in dose-response format in a single experiment. Analysis of the resulting multidimensional dataset revealed subclusters of both inhibitors and kinases with closely correlated activities. The approach also identified activities for the p38 inhibitor BIRB796 and the dual src/abl inhibitor BMS-354825 and exposed the expected side activities for Glivec/STI571, including cellular inhibition of c-kit and platelet-derived growth factor receptor. This methodology provides a powerful tool for unraveling the cellular biology and molecular pharmacology of both naturally occurring and synthetic chemical diversity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16492761      PMCID: PMC1413928          DOI: 10.1073/pnas.0511292103

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  35 in total

1.  A concise and traceless linker strategy toward combinatorial libraries of 2,6,9-substituted purines.

Authors:  S Ding; N S Gray; Q Ding; P G Schultz
Journal:  J Org Chem       Date:  2001-11-30       Impact factor: 4.354

Review 2.  Oncogenic kinase signalling.

Authors:  P Blume-Jensen; T Hunter
Journal:  Nature       Date:  2001-05-17       Impact factor: 49.962

3.  Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr/abl protein.

Authors:  G Q Daley; D Baltimore
Journal:  Proc Natl Acad Sci U S A       Date:  1988-12       Impact factor: 11.205

4.  The novel activation of ABL by fusion to an ets-related gene, TEL.

Authors:  P Papadopoulos; S A Ridge; C A Boucher; C Stocking; L M Wiedemann
Journal:  Cancer Res       Date:  1995-01-01       Impact factor: 12.701

5.  Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines.

Authors:  F Hayakawa; M Towatari; H Kiyoi; M Tanimoto; T Kitamura; H Saito; T Naoe
Journal:  Oncogene       Date:  2000-02-03       Impact factor: 9.867

6.  Mining the National Cancer Institute's tumor-screening database: identification of compounds with similar cellular activities.

Authors:  Alfred A Rabow; Robert H Shoemaker; Edward A Sausville; David G Covell
Journal:  J Med Chem       Date:  2002-02-14       Impact factor: 7.446

7.  Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction.

Authors:  M Boolell; M J Allen; S A Ballard; S Gepi-Attee; G J Muirhead; A M Naylor; I H Osterloh; C Gingell
Journal:  Int J Impot Res       Date:  1996-06       Impact factor: 2.896

8.  A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia.

Authors:  V Lacronique; A Boureux; V D Valle; H Poirel; C T Quang; M Mauchauffé; C Berthou; M Lessard; R Berger; J Ghysdael; O A Bernard
Journal:  Science       Date:  1997-11-14       Impact factor: 47.728

9.  Loss of response to imatinib: mechanisms and management.

Authors:  Neil P Shah
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2005
View more
  67 in total

1.  Comprehensive analysis of kinase inhibitor selectivity.

Authors:  Mindy I Davis; Jeremy P Hunt; Sanna Herrgard; Pietro Ciceri; Lisa M Wodicka; Gabriel Pallares; Michael Hocker; Daniel K Treiber; Patrick P Zarrinkar
Journal:  Nat Biotechnol       Date:  2011-10-30       Impact factor: 54.908

Review 2.  Targeting Eph receptors with peptides and small molecules: progress and challenges.

Authors:  Roberta Noberini; Ilaria Lamberto; Elena B Pasquale
Journal:  Semin Cell Dev Biol       Date:  2011-10-25       Impact factor: 7.727

3.  BCR-ABL signaling: A new STATus in CML.

Authors:  Doriano Fabbro
Journal:  Nat Chem Biol       Date:  2012-02-15       Impact factor: 15.040

4.  An amino-indazole scaffold with spectrum selective kinase inhibition of FLT3, PDGFRα and kit.

Authors:  Xianming Deng; Wenjun Zhou; Ellen Weisberg; Jinhua Wang; Jianming Zhang; Takaaki Sasaki; Erik Nelson; James D Griffin; Pasi A Jänne; Nathanael S Gray
Journal:  Bioorg Med Chem Lett       Date:  2012-06-06       Impact factor: 2.823

5.  Discovery of RAF265: A Potent mut-B-RAF Inhibitor for the Treatment of Metastatic Melanoma.

Authors:  Teresa E Williams; Sharadha Subramanian; Joelle Verhagen; Christopher M McBride; Abran Costales; Leonard Sung; William Antonios-McCrea; Maureen McKenna; Alicia K Louie; Savithri Ramurthy; Barry Levine; Cynthia M Shafer; Timothy Machajewski; Paul A Renhowe; Brent A Appleton; Payman Amiri; James Chou; Darrin Stuart; Kimberly Aardalen; Daniel Poon
Journal:  ACS Med Chem Lett       Date:  2015-08-03       Impact factor: 4.345

Review 6.  Functional genomics to uncover drug mechanism of action.

Authors:  Sebastian M B Nijman
Journal:  Nat Chem Biol       Date:  2015-11-17       Impact factor: 15.040

7.  Computational Modeling of Kinase Inhibitor Selectivity.

Authors:  Govindan Subramanian; Manish Sud
Journal:  ACS Med Chem Lett       Date:  2010-07-28       Impact factor: 4.345

Review 8.  Eph receptors and ephrins in cancer: bidirectional signalling and beyond.

Authors:  Elena B Pasquale
Journal:  Nat Rev Cancer       Date:  2010-03       Impact factor: 60.716

9.  Clinical stage EGFR inhibitors irreversibly alkylate Bmx kinase.

Authors:  Wooyoung Hur; Anastasia Velentza; Sungjoon Kim; Laura Flatauer; Xinnong Jiang; David Valente; Daniel E Mason; Melissa Suzuki; Brad Larson; Jianming Zhang; Anna Zagorska; Michael Didonato; Advait Nagle; Markus Warmuth; Steven P Balk; Eric C Peters; Nathanael S Gray
Journal:  Bioorg Med Chem Lett       Date:  2008-07-18       Impact factor: 2.823

10.  High-throughput screening and chemical biology: new approaches for understanding circadian clock mechanisms.

Authors:  Tsuyoshi Hirota; Steve A Kay
Journal:  Chem Biol       Date:  2009-09-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.